Lyell Immunopharma Announces Results of 2026 Annual Meeting of Stockholders

Lyell Immunopharma, Inc. held its 2026 Annual Meeting of Stockholders on June 10, 2026. During the meeting, stockholders voted on three key proposals. First, the stockholders elected three Class II directors—Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin—to serve on the Board of Directors until the 2029 annual meeting. Second, the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Finally, stockholders approved, on an advisory basis, the compensation of the company's named executive officers as disclosed in the proxy statement. A total of 15,706,826 shares, representing approximately 67.31% of the outstanding common stock as of the record date, were present or represented by proxy, constituting a quorum. The filing confirms the results of these standard corporate governance matters and does not report any new clinical or operational developments.